Market Newsdesk

NEW YORK, Jan. 6, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for ISR, CHNG, DBVT, HEXO, and ORTX.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• ISR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ISR&prnumber=010620211 
• CHNG: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CHNG&prnumber=010620211 
• DBVT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=DBVT&prnumber=010620211 
• HEXO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=HEXO&prnumber=010620211 
• ORTX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=ORTX&prnumber=010620211 

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-isoray-change-healthcare-dbv-technologies-hexo-corp-or-orchard-therapeutics-301201980.html

SOURCE InvestorsObserver

VANCOUVER, BC, Jan. 6, 2021 /PRNewswire/ – Heatherdale Resources Ltd. (“Heatherdale” or the “Company“) (TSXV: HTR) announces that the Phase I surface diamond drilling program was recently completed at its 100%-owned Niblack copper-gold-silver-zinc project, located near tidewater in southeast Alaska.  Crews have returned home for the holiday break with drilling expected to recommence in February.  During the fall 2020 program, 10 holes were completed totaling 1,774 meters.  Based on encouraging visual results in the first four planned holes, all drilling during this program targeted the historic Niblack mine area, with step-out drilling at the Lookout Deposit deferred until 2021.  All assay results are pending.

“We are exceptionally encouraged with our first round of drilling, targeting some of the highest-grade massive-sulphide mineralization that has been recognized on the Property,” said Robert McLeod, President and CEO of Heatherdale.  “Our drilling has confirmed that the newgeological theory, developed since the last drilling program eight years ago, has recognized that a synform hosts the VMS-style mineralization at the old mine, rather than an antiform.  This confirmation has significantly increased the exploration potential of this area and the entire Niblack Property.”

The 2020 drilling program at Niblack targeted both the east and west limbs of the fold as well as structurally thickening within the fold hinge, located approximately 140 meters below surface and down-plunge from the historic mine workings.  Heatherdale intends to follow-up this area with additional surface drilling to the north and south of the historic mine, with the intent of delineating sufficient extent and continuity for an initial Mineral Resource estimate at this Zone.  This drilling will be in addition to the underground exploration and resource expansion drilling at the Lookout Deposit, located over one kilometer south of the historic mine.

Significant underground rehabilitation of the 850 meter long, production-size exploration drift was completed which will enable underground drilling, ideally with two underground rigs, commencing in February, 2021.  With the Niblack Project located on tidewater and a barge camp to support operations, year-round cost-effective exploration is possible at the Niblack Property.

Historic Niblack Mine

The historic Niblack Mine is located over 1,000 meters north of current Mineral Resources at Lookout and Trio Zones.  Direct-shipping copper mineralization was discovered at Niblack Anchorage in 1899 with production from 1902 through 1908.  According to Alaska Territorial Government Records, 30,000 tons were mined averaging 3.2% Cu, 1.3 g/t Au, and 21 g/t Ag.  22 holes were completed by previous operators.  Previous drill intercepts include: LO-065 which intersected 4.6 meters averaging 5.8% Cu, 2.3 g/t Au, 3.8% Zn and 63.2 g/t Ag, as well as LO-067 which intersected 4.9 meters averaging 5.1% Cu, 13.1 g/t Au, 4.0% Zn and 149.1 g/t Ag. 

High-grade VMS-style mineralization outcrops along the shoreline adjacent to the historic workings.  A geological reinterpretation of the host-rock units, which was confirmed during the 2020 drilling program, supported by radiometric age-dating has suggested that the mineralization is hosted within an overturned antiform type fold (synform).  This structure appears to plunge to the east, suggesting mineralization is wide open for expansion along trend and plunge from the historic stopes and high-grade historic intercepts.  Sea-floor exhalative mineralization includes well-preserved volcanic textures of massive chalcopyrite, sphalerite and pyrite often associated with silica-magnetite exhalative iron-formation.

Highlights of previous drilling at the historic Niblack mine include:

Covid-19 Protocol

Heatherdale has worked with the State of Alaska to develop and implement a robust Community/Workforce Protective Plan under the guidance of Governor Dunleavy’s Health Mandate 10 and recent executive action to limit the spread of COVID-19 to Alaskan communities and protect workers at the Niblack Project.  No Covid-19 cases have been reported to-date by Heatherdale’s team or Contractors.

QA/QC and Qualified Persons

The Qualified Person under NI 43-101 for the 2020 exploration program at the Niblack Project is Marilyne Lacasse, P.Geo,  Consulting Geologist for Heatherdale Resources Ltd.  Drill core was cut in-half with a diamond saw, with one-half placed in sealed bags and shipped with chain of custody controls to ALS Labs in Vancouver, BC, for sample preparation, and analysis.  A rigorous Quality Control/Quality Assurance program, including the insertion of Standards and Blanks, duplicate analysis and third-party labs checks will be implemented.  Robert McLeod, P.Geo, President and CEO of Heatherdale Resources Ltd, a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release, in addition to Ms. Lacasse.

About Heatherdale

Heatherdale Resources Ltd.’s founding vision is to be an industry leader in transparency, inclusion and innovation.  Guided by our Vision and through collaboration with local and Indigenous communities and stakeholders, Heatherdale builds shareholder value through our technical expertise in mineral exploration, engineering and permitting. The Company holds a 100% interest in the high-grade Niblack copper-gold-zinc-silver VMS project, located adjacent to tidewater in southeast Alaska.  For more information on Heatherdale, please visit the Company’s website at www.heatherdaleresources.com.

On behalf of the Board
of Directors

“Robert McLeod”

Robert McLeod, P.Geo
President, CEO and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements:

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws.  Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward
–
looking statements”, are not historical facts, are made as of the date of this news release. Forward–looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things, market volatility; the state of the financial markets for the Company’s securities; and changes in the Company’s business plans. In making the forward looking statements in this news release, the Company has applied several material assumptions that the Company believes are reasonable, including without limitation, that the Company will continue with its stated business objectives. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. The Company seeks safe harbor.

The Company’s “Mineral Resource Estimate” refers to a November 2011 NI 43-101 Report authored by SRK Consulting Independent of the Company and

Deon Van Der Heever, Pr. Sci. Nat., Hunter Dickinson Inc., a Qualified Person who was not independent of the Company. 

 

Net Smelter Return (NSR) cutoff uses long-term metal forecasts: gold US$1,150/oz, silver US$20.00/oz, copper US$2.50/lb, and zinc US$1.00/lb; Recoveries (used for all NSR calculations) to Cu concentrate of 95% Cu, 56% Au and 53% Ag with payable metal factors of 96.5% for Cu, 90.7% for Au, and 89.5% for Ag; to Zn concentrate of 93% Zn, 16% Au, and 24% Ag with payable metal factors of 85% for Zn, 80% for Au and 20% for Ag. Detailed engineering studies will determine the best cutoff.

For more information on the Company, investors should review the Company’s continuous disclosure filings that are available at www.sedar.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/heatherdale-resources-exploration-drilling-update-at-the-niblack-copper-gold-silver-zinc-project-alaska-301201695.html

SOURCE Heatherdale Resources Limited

BOSTON, Jan. 6, 2021 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. The transaction was unanimously approved by both the NeuroBo Pharmaceuticals’ and ANA Therapeutics’ Boards of Directors.

“This is an exciting and transformative acquisition for NeuroBo that expands our pipeline with a late-stage clinical development program that addresses the urgent need for new treatments to address COVID-19, a highly-infectious and often deadly virus,” stated Richard J. Kang, Ph.D., President and Chief Executive Officer of NeuroBo. “ANA-001 is advancing through the 505(b)(2) clinical pathway, which allows us to leverage earlier data on niclosamide and streamlines and accelerates the timelines to bring this potentially life-saving therapy to patients suffering with COVID-19. As a result, the development timeline supports a number of value-creating milestones over the coming 12 to 18 months, including the data readout of the Phase 2 portion of the trial, expected in the third quarter of 2021.” 

“While the introduction of vaccines is expected to play a significant role in stemming the tide of the COVID-19 pandemic, the ongoing complexities and mutation of the disease will require therapies to treat the infected population for the foreseeable future,” commented Irene Kim, Chair of the Board of NeuroBo. “Similar to influenza, taking a COVID-19 vaccine and therapy could become an annual routine. Preclinical data has demonstrated niclosamide’s ability to inhibit viral replication of SARS-CoV-2 and underscores ANA-001’s potential to effectively address the ongoing need for safe and effective COVID-19 treatments on a global scale.” 

“We are delighted to join with the NeuroBo team in order to bring ANA-001 to the millions of patients infected with COVID-19. NeuroBo has the leadership and platform to support the accelerated development of this important compound as a potential treatment for this viral pandemic,” said Akash Bakshi, Chief Executive Officer of ANA Therapeutics. 

About Niclosamide and ANA-001

ANA-001 is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA-001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. In preclinical research by an independent academic group published in Antimicrobial Agents and Chemotherapy, niclosamide inhibited viral replication in vitro and was more potent than remdesivir in the same assay.

Specifically, studies have shown that niclosamide prevents replication of SARS-CoV-2 at very low concentrations and that the compound appears to exhibit three distinct mechanisms of action: 1) acting as a potent antiviral to a broad homology of other viruses including influenza; 2) reducing inflammation without suppressing the immune system; and 3) providing bronchodilation, which is a useful pulmonary mechanism for at-risk patients with underlying cardiovascular and/or pulmonary conditions.

As a result, the company believes ANA-001 has the potential to reduce the viral load and inflammation associated with cytokine dysregulation, acute respiratory distress syndrome (ARDS), and coagulation abnormalities and thus improve time to clinical improvement as defined as hospital discharge recorded using the WHO Ordinal Scale for Clinical Improvement.

The company believes ANA-001 has distinct competitive advantages in this market, including (1) offering an effective treatment for moderate to severe COVID-19 (patients not requiring ventilators); (2) having 3+ year marketing exclusivity in the U.S. upon U.S. Food and Drug Administration (FDA) approval; (3) providing ease of administration via a capsule formulation and potential to dramatically lower overall treatment cost; and (4) possessing a proven safety profile (generic niclosamide has been used safely for 50 years as a treatment for tapeworm infections).

Clinical Development Plans for ANA-001

In October 2020, a Phase 2/3 clinical trial evaluating ANA-001 as a treatment for COVID-19 was initiated.  The two-part Phase 2/3 multi-center, double blind, placebo-controlled study to assess the safety, tolerability, and efficacy of ANA-001 is being conducted at up to 20 clinical sites in the U.S. In both phases of the study, hospitalized patients with moderate to severe COVID-19 (patients not requiring ventilators) will be administered a seven-day course of ANA-001 (niclosamide capsules) in addition to standard-of-care treatment. The first phase of the trial will enroll 60 patients. The primary objective of the first phase of the trial is to assess safety and tolerability; secondary objectives include measurements of efficacy (median time to hospital discharge) and pharmacokinetics. The company expects to complete enrollment of the first phase of the study and to have topline data from this segment of the trial in the third quarter of 2021. 

The second phase of the trial is expected to enroll several hundred patients, with the primary endpoints of the study being median time to hospital discharge, safety and tolerability. Secondary objectives will evaluate clinical improvement and the need and duration for rescue therapy.

For more information on this clinical trial, please visit: www.clinicaltrials.gov, NCT04603924. 

Acquisition Details

Under the terms of the acquisition agreement, ANA became a wholly-owned subsidiary of NeuroBo and ANA equity holders were issued an aggregate of approximately 3.24 million shares of Neurobo common stock, representing 19.7% of NeuroBo’s outstanding shares. ANA shareholders will receive additional payments (in cash or NeuroBo common shares) upon the achievement of various development and net sales milestones for ANA-001 and will also receive royalties based on net sales of ANA-001.

Three key executives from ANA Therapeutics have joined the NeuroBo management team including, Akash Bakshi, as Senior Vice President and Chief Operating Officer, Nadja Mannowetz, Ph.D., as Senior Vice President, and Andrew Bartynski, Ph.D., as Senior Vice President. In addition, Mr. Bakshi has joined NeuroBo’s board of directors. 

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, has a current portfolio of four drug candidates. The company’s recently acquired ANA-001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA-001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. The company’s NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Due to global COVID-19 crisis, a planned Phase 3 study was postponed. In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. NeuroBo’s NB-02 drug candidate is focused on the treatment of Alzheimer’s disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The company’s third program, Gemcabene, was developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease.

For more information visit: https://www.neurobopharma.com.

Forward Looking Statements

Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the development timeline for niclosamide for the treatment of COVID-19, the market size for COVID-19-related therapeutics and the competitive advantages of ANA-001, the potential benefits of ANA-001 as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators), and potential milestone payments and royalties that may become due to the former equity holders of ANA under the acquisition agreement. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties include, but are not limited to: the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities; the effect of future milestone payments and royalties specified in the acquisition agreement on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo’s business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo’s ability to continue as a going concern; the timing of completion of NeuroBo’s planned clinical trials, including with respect to ANA-001; the timing of the availability of data from NeuroBo’s clinical trials, including with respect to ANA-001;  the clinical utility, potential benefits and market acceptance of NeuroBo’s product candidates, including ANA-001; ; and NeuroBo’s need for additional financing to fulfill its stated goals; and other factors discussed in the “Risk Factors” section of NeuroBo’s Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent NeuroBo’s views as of the date hereof. NeuroBo anticipates that subsequent events and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing NeuroBo’s views as of any date subsequent to the date hereof.

Contacts:

Rx Communications Group

Michael Miller

+1-917-633-6086
[email protected]

View original content:http://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-acquires-ana-therapeutics-for-late-stage-oral-antiviral-development-program-301201781.html

SOURCE NeuroBo Pharmaceuticals, Inc.

SAN JOSE, Calif., Jan. 6, 2021 /PRNewswire/ — Sanmina Corporation (NASDAQ: SANM), a leading integrated manufacturing solutions company that manufactures some of the world’s most complex and innovative electronic, optical and mechanical products, today announced that Hari Pillai has rejoined the company as President of Components Technology. Mr. Pillai brings to Sanmina more than 25 years of operational leadership experience in the technology industry. 

The addition of Mr. Pillai to the organization aligns with the Company’s previously announced plan to operate in three businesses to unlock the total value of Sanmina. Mr. Pillai joins two distinguished individuals and rounds out the leadership for Integrated Manufacturing Solutions (IMS), SCI (defense products and system builds) and Components Technology (advanced interconnect technology and mechanical systems).

“We are excited to have Hari rejoin the organization. His broad experience and knowledge of Sanmina, combined with the strength of our leadership team, is unsurpassed in the industry,” stated Jure Sola, Chairman and CEO of Sanmina. “His strong background leading global operations in high complexity, heavily regulated markets is well aligned with Sanmina’s long term strategy. I am confident that Hari’s leadership will drive the Component Technology business strategy to accelerate profitable growth and capitalize on synergies across the organization.”

Mr. Pillai most recently served as Executive Vice President, Customer Installations Group at Bloom Energy, where he was responsible for leading a team of professionals from engineering, program management and supply chain management, ensuring high quality installations. Prior to Bloom, he was Chief Executive Officer and President of Contec Holdings, a global provider of test technology and OEM warranty services to broadband service providers. Mr. Pillai’s career includes 17 years with Sanmina where he held various leadership roles including President and Chief Operating Officer and Executive Vice President, EMS division. During his tenure, he was instrumental in the transformation of Sanmina to a leading end-to-end global EMS provider.  

Mr. Pillai is a graduate of Trinity College at the University of Dublin in Ireland, where he received his B.Sc. in Management and of the Smurfit School of Business at University College Dublin where he received his Master in Business (MBS) with First Class Honors.

About Sanmina

Sanmina Corporation, a Fortune 500 company is a leading integrated manufacturing solutions provider serving the fastest growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina provides end-to-end manufacturing solutions, delivering superior quality and support to Original Equipment Manufacturers (OEMs) primarily in the communications networks, cloud solutions, industrial, defense, medical and automotive. Sanmina has facilities strategically located in key regions throughout the world. More information about the Company is available at www.sanmina.com.

Logo – https://mma.prnewswire.com/media/10544/SANMINA_CORPORATION_LOGO.jpg

View original content:http://www.prnewswire.com/news-releases/hari-pillai-rejoins-sanmina-as-president-of-components-technology-301201805.html

SOURCE Sanmina Corporation

PITTSBURGH, Jan. 6, 2021 /PRNewswire/ — Allegheny Technologies Incorporated (NYSE: ATI) will provide live Internet listening access to its conference call with the financial community scheduled for Thursday, January 28, 2021 at 8:30 a.m. ET.  The conference call will be conducted after the Company’s planned release of fourth quarter and full-year 2020 results.  The conference call will be broadcast, and accompanying presentation slides will be available, at ATImetals.com.  To access the broadcast, visit ATImetals.com and select “Conference Call.”  Conference call replay will be available on ATImetals.com.

Solving the World’s Challenges through Materials Science

ATI (NYSE: ATI) is a $3 billion global manufacturer solving the world’s most difficult challenges through materials science; advanced, integrated process technologies; and relentlessly innovative people. We serve customers whose demanding applications need to fly higher, dig deeper, stand stronger, and last longer— anywhere on, above, or below the earth. We partner to create new specialty materials in forms that deliver ultimate performance and long-term value in applications like jet engine forgings and 3D-printed aerospace components. We produce powders for forging and additive manufacturing; rolled materials, and finished components. Our specialty materials withstand extremes of temperature, stress and corrosion to improve and protect human lives every day. Learn more at ATIMetals.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/allegheny-technologies-announces-webcast-of-conference-call-for-fourth-quarter-and-full-year-2020-results-301201610.html

SOURCE Allegheny Technologies

LISLE, Ill., Jan. 6, 2021 /PRNewswire/ — Molex, a leading global connectivity and electronics solutions provider, unveiled results of a global survey of automotive decision makers depicting top trends and technologies impacting “car of the future” strategies and business decisions. Survey findings validate the critical role of data, software and networking in enabling electrification and connectivity—identified as the two most important areas of innovation.

“It’s an exciting time in the automotive industry, and this survey underscores the accelerated pace of investment and innovation,” said Mike Bloomgren, SVP, president, Transportation & Industrial Solutions, Molex. “The results also reinforce our mission to design and deliver critical electronics solutions that form the central nervous system of tomorrow’s connected cars.”

Molex commissioned Dimensional Research to conduct The Future of Automotive survey in November 2020, polling 230 qualified participants in engineering, product, procurement, R&D, supply chain, innovation or strategy roles at automotive companies with at least 1,000 employees. Survey respondents were asked questions designed to help them visualize what an average new car purchased in 2030 might be like, including top features, initiatives and innovations.

Key findings include:

• 91% of respondents say cars will be either fully electric (64%) or hybrid (27%)
• 97% expect “range anxiety” to be solved by 2030
• 94% expect cars to include autonomous driving; only 28% envision fully self-driving cars
• 56% believe 2030 cars will be at least 50% more expensive than today’s cars

When asked to identify top areas in the overall ecosystem with the most potential to reduce the price of a 2030 car, battery cost savings (40%), software integration (34%) and manufacturing processes (32%) led the way. In addition, 96% agreed the car of the future will require manufacturing factory innovations.

Top Features, Technologies and Innovations

According to the survey respondents, the top three features most likely to be standard by 2030 are high-speed WiFi, wireless charging and car-to-car communication. In selecting the five most important innovation areas in the next decade, respondents picked electrification (38%), connectivity (33%), passenger safety (29%), quality and reliability (28%), and software-defined infrastructure (27%).

Moreover, 60% of those polled favor the ability to deliver innovation via software as a priority, encompassing the intelligence needed for autonomous driving, advanced algorithms to reduce energy consumption, remote updates of new capabilities and customized driving experiences.

Across the board, participants reported customer demand and technology innovations will impact future car developments, especially in speeding green or socially responsible initiatives, ranging from zero-emission vehicles to zero-waste production.

Tech Companies and China Gain Momentum

While 44% of survey respondents envision established automakers driving development of an average car purchased in 2030, 32% cited increasing traction by technology companies. Companies such as Apple, Google and Microsoft are expected to gain momentum because of their expertise in user experience and Human Machine Interfaces. Equally important is industry sentiment that China is most likely to produce the car of the future first, followed by the U.S., Japan and Germany.

Overcoming Obstacles is Prioritized

Overwhelmingly, participants report major technology challenges to delivering innovation, with 44% citing insufficient battery life and 36% reporting obstacles getting electronics and software to operate in extreme scenarios. Additionally, 33% reported challenges in attaining hard-to-find expertise in electrification, 5G, security and other needed technologies.

Molex Automotive: Experience Counts

For nearly 30 years, Molex has played a vital role in the automotive industry, especially in addressing demand for flawless interconnectivity of mobile devices and data services. In that time, the company has supplied more than 95% of engine control and powertrain connectivity solutions for a major automotive OEM. Molex brings its heritage in networking and longstanding reputation for product quality and customer collaboration to meet growing consumer needs across the automotive ecosystem, spanning electrification, Advanced Driver-Assistance Systems (ADAS), automotive high-speed networking, vehicle antenna systems, connected mobility solutions and vehicle-to-everything communications (V2X).

About Molex

Molex makes a connected world possible by enabling technologies that transform the future and improve lives. With a presence in more than 40 countries, Molex offers a complete range of connectivity products, services and solutions for the data communications, medical, industrial, automotive and consumer electronics industries. For more information visit www.molex.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/molex-releases-results-of-global-automotive-survey-on-the-car-of-the-future-301201655.html

SOURCE Molex Incorporated

TINTON FALLS, N.J., Jan. 6, 2021 /PRNewswire/ — Commvault (NASDAQ: CVLT) – Commvault will release the Company’s financial results for its fiscal third quarter ended December 31, 2020, on Wednesday, January 27, 2021 before the market opens. An earnings letter discussing the financial results and quarterly highlights will be posted at http://ir.commvault.com.

The FutureReady Investor Event will begin at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) to discuss quarterly results, our long-term vision and strategy and provide a multi-year business outlook. Investors can register and access the live webcast by visiting the event site. The meeting will include a slide presentation and participants are encouraged to view the presentation via webcast at the event site.

An archived webcast of this event will also be available following its conclusion at http://ir.commvault.com.

Supporting Resources

• Learn more about Commvault

About Commvault
Commvault is the recognized leader in data backup and recovery. Commvault’s converged data management solution redefines what backup means for the progressive enterprise through solutions that protect, manage and use their most critical asset — their data. Commvault software, solutions and services are available from the company and through a global ecosystem of trusted partners. Commvault employs more than 2,600 highly-skilled individuals across markets worldwide, is publicly traded on NASDAQ (CVLT), and is headquartered in Tinton Falls, New Jersey in the United States. To learn more about Commvault visit www.commvault.com

Safe Harbor Statement: Customers’ results may differ materially from those stated herein; Commvault does not guarantee that all customers can achieve benefits similar to those stated above. This press release may contain forward-looking statements, including statements regarding financial projections, which are subject to risks and uncertainties, such as competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of software products and related services, general economic conditions and others. Statements regarding Commvault’s beliefs, plans, expectations or intentions regarding the future are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from anticipated results. Commvault does not undertake to update its forward-looking statements. The development and timing of any product release as well as any of its features or functionality remain at our sole discretion.

©1999-2021 Commvault Systems, Inc. All rights reserved. Commvault, Commvault and logo, the “C hexagon” logo, Commvault Systems, Commvault HyperScale, ScaleProtect, Commvault OnePass, Unified Data Management, Quick Recovery, QR, CommNet, GridStor, Vault Tracker, InnerVault, Quick Snap, QSnap, IntelliSnap, Recovery Director, CommServe, CommCell, APSS, Commvault Edge, Commvault GO, Commvault Advantage, Commvault Complete, Commvault Activate, Commvault Orchestrate, Commvault Command Center, Hedvig, Universal Data Plane, the “Cube” logo, Metallic, the “M Wave” logo, and CommValue are trademarks or registered trademarks of Commvault Systems, Inc. All other third party brands, products, service names, trademarks, or registered service marks are the property of and used to identify the products or services of their respective owners. All specifications are subject to change without notice.

View original content to download multimedia:http://www.prnewswire.com/news-releases/commvault-to-release-third-quarter-fiscal-2021-earnings-results-and-host-futureready-investor-event-301201592.html

SOURCE Commvault

DENVER, Jan. 6, 2021 /PRNewswire/ — Akerna (Nasdaq: KERN) (“Akerna” or the “Company”), a leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), is pleased to provide an update on the continued success of MJ Analytics, a next-generation cannabis data analytics platform.

Made possible through Domo’s modern business intelligence platform, MJ Analytics offers enterprise-level data tools, providing Akerna’s partners with unparalleled access and insight into the complete cannabis supply chain, from seed to sale. 

Within less than 90 days of launching MJ Analytics, the platform has generated a six figure increase in sales and helped clients reduce manual reporting workflows by 90% through the use of scheduled reports. With a 95% positive product feedback based on recent surveys, MJ Analytics is proving its value as a first-of-its-kind actionable insights product.

Since launch, MJ Analytics has:

• Processed a total of 5.1 million queries
• Averaged 3.6k queries a day with peaks of 20k queries during month ends
• Signed up 40 clients for Premium Analytics, through either a trial or paid subscription
• Migrated MJ Platform clients over to Standard Analytics

“We are thrilled the find that our clients are enjoying the simplified user experience and easy-to-understand data visualizations that MJ Analytics provides,” said Hanks Wang, Director of Data & Analytics, Akerna. “As new cannabis markets start to open over the coming year, we look forward to helping both burgeoning brands and enterprise-class businesses alike streamline their operations.”

“One of Domo’s key differentiators is its ability to support companies of any size in creating more value for customers and new revenue streams from their business data,” said Robert Davy, vice president of customer success. “We’re proud, through our Domo Everywhere offering, to help innovative companies like Akerna use data in new ways to drive their business forward.”

About Akerna
Akerna (Nasdaq: KERN) is an enterprise software company focused on compliantly serving the cannabis, hemp, and CBD industry. Based in Denver, Colorado, the Company’s mission is to create the world’s most transparent and accountable supply chain by building a cannabis technology ecosystem connecting data points across the global cannabis supply chain from seed to sale to self. First launched in 2010, Akerna has tracked more than $20 billion in cannabis sales to date and is the first cannabis software company listed on Nasdaq.

Using connected data and information to propel the cannabis industry forward, Akerna empowers businesses, governments, patients, and consumers to make smart decisions. The Company’s cornerstone technology, MJ Platform, the world’s leading infrastructure as a service platform powers retailers, manufacturers, brands, distributors, and cultivators. Akerna also offers a complete suite of professional consulting services and data analytics for businesses as well as solo sciences, MJ Freeway, Leaf Data Systems, Trellis, and Ample Organics.

For more information, visit https://www.akerna.com/

Forward-Looking Statements:
Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Such forward-looking statements include but are not limited to statements regarding the ability of the MJ Platform team to help operators make decisions through analytics and reporting. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of significant known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside Akerna’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others that may affect actual results or outcomes, include (i) Akerna’s ability to maintain relationships with customers and suppliers and retain its management and key employees, (ii) changes in applicable laws or regulations, (iii) changes in the market place due to the coronavirus pandemic or other market factors, (iv) and other risks and uncertainties disclosed from time to time in Akerna’s filings with the U.S. Securities and Exchange Commission, including those under “Risk Factors” therein.  You are cautioned not to place undue reliance on forward-looking statements. All information herein speaks only as of the date hereof, in the case of information about Akerna, or the date of such information, in the case of information from persons other than Akerna. Akerna undertakes no duty to update or revise the information contained herein. Forecasts and estimates regarding Akerna’s industry and end markets are based on sources believed to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mj-analytics-an-akerna-product-built-on-domos-modern-bi-platform-generates-six-figure-sales-increase-301201777.html

SOURCE Akerna

TORONTO, Jan. 6, 2021 /PRNewswire/ — Aleafia Health Inc. (TSX: AH, OTC: ALEAF), a Canadian cannabis health and wellness company, today announced that Geoffrey Benic, CEO, will present live at VirtualInvestorConferences.com on January 7.  

DATE: January 7^th, 2021

TIME: 11:00 AM ET

LINK: https://bit.ly/3ntV6uT

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

About Virtual Investor Conferences
^®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aleafia-health-to-webcast-live-at-virtualinvestorconferencescom-january-7th-301199873.html

SOURCE VirtualInvestorConferences.com